Long-term data from APPROACH: phase 1/2a randomized, double-blind, placebo-controlled study evaluating safety/tolerability and immunogenicity of vaccine regimens using combinations of Ad26.Mos.HIV, MVA-mosaic and gp140 envelope protein

被引：0
|
作者：
Tomaka, F. [1 ]
Stieh, D. [2 ]
Barouch, D. [3 ]
Robb, M. [4 ,5 ]
Michael, N. [4 ]
Tomaras, G. [6 ]
Alter, G. [7 ]
McElrath, J. [8 ]
Lavreys, L. [9 ]
Nijs, S. [9 ]
Callewaert, K. [2 ]
Hendriks, J. [2 ]
Euler, Z. [2 ]
Pau, M. [2 ]
Schuitemaker, H. [2 ]
机构：
[1] Janssen Res & Dev LLC, Titusville, NJ USA
[2] Janssen Vaccines & Prevent BV, Leiden, Netherlands
[3] Harvard Med Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[4] Walter Reed Army Inst Res, Mil HIV Res Program, Silver Spring, MD USA
[5] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA
[6] Duke Univ, Duke Human Vaccine Inst, Durham, NC 27706 USA
[7] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA
[8] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA
[9] Janssen Infect Dis BV, Beerse, Belgium
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
TUAA0104
引用
收藏
页码：2 / 3
页数：2
相关论文
共 17 条
  • [1] ASCENT: Phase 2a, randomized, double-blind, placebo controlled study evaluating safety and immunogenicity of two HIV-1 prophylactic vaccine regimens comprising Ad26. Mos4. HIV and either clade C gp140 or bivalent gp140
    Stieh, D. J.
    Tomaka, F.
    Comeaux, C. A.
    Nijs, S.
    Callewaert, K.
    Hendriks, J.
    Euler, Z.
    Tomaras, G. D.
    Alter, G.
    Kublin, J.
    Corey, L.
    McElrath, J.
    Swann, E.
    Robb, M.
    Michael, N.
    Marovich, M.
    Pau, M. G.
    Barouch, D. H.
    Schuitemaker, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 98 - 98
  • [2] Two-year post-vaccination follow-up from APPROACH: Phase 1/2a randomized study evaluating safety and immunogenicity of prophylactic HIV vaccine regimens combining Ad26.Mos.HIV and gp140 envelope protein
    Tomaka, F.
    Stieh, D. J.
    Barouch, D. H.
    Robb, M. L.
    Michael, N. L.
    Lavreys, L.
    Nijs, S.
    Callewaert, K.
    Hendriks, J.
    Euler, Z.
    Pau, M. G.
    Schuitemaker, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 19 - 19
  • [3] Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study
    Comeaux, Christy A.
    Bart, Stephan
    Bastian, Arangassery Rosemary
    Klyashtornyy, Vladislav
    De Paepe, Els
    Omoruyi, Edmund
    van der Fits, Leslie
    van Heesbeen, Roy
    Heijnen, Esther
    Callendret, Benoit
    Sadoff, Jerald
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (01): : 19 - 29
  • [4] Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study
    Comeaux, Christy A.
    Bart, Stephan
    Bastian, Arangassery Rosemary
    Klyashtornyy, Vladislav
    De Paepe, Els
    Omoruyi, Edmund
    van der Fits, Leslie
    van Heesbeen, Roy
    Heijnen, Esther
    Callendret, Benoit
    Sadoff, Jerald
    JOURNAL OF INFECTIOUS DISEASES, 2023, 229 (01): : 19 - 29
  • [5] HPX1002/IPCAVD010: a randomized controlled trial evaluating the safety and immunogenicity of shorter and simpler vaccine schedules using Ad26.Mos.HIV combined with gp140 Env protein
    Stephenson, K.
    Ansel, J.
    Walsh, S.
    Tan, C. S.
    Ananos, D.
    Yanez, A.
    Peter, L.
    Tomaka, F.
    Stieh, D.
    Hendriks, J.
    Nijs, S.
    Truyers, C.
    Pau, M. Grazia
    Seaman, M.
    Walker, B.
    Schuitemaker, H.
    Barouch, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 3 - 3
  • [6] Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
    Baden, Lindsey R.
    Stieh, DanielJ
    Sarnecki, Michal
    Walsh, Stephen R.
    Tomaras, Georgia D.
    Kublin, James G.
    McElrath, M. Juliana
    Alter, Galit
    Ferrari, Guido
    Montefiori, David
    Mann, Philipp
    Nijs, Steven
    Callewaert, Katleen
    Goepfert, Paul
    Edupuganti, Srilatha
    Karita, Etienne
    Langedijk, Johannes P.
    Wegmann, Frank
    Corey, Lawrence
    Pau, Maria G.
    Barouch, Dan H.
    Schuitemaker, Hanneke
    Tomaka, Frank
    LANCET HIV, 2020, 7 (10): : E688 - E698
  • [7] Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study
    van Heesbeen, Roy
    Bastian, Arangassery Rosemary
    Omoruyi, Edmund
    Rosen, Jeffrey
    Comeaux, Christy A.
    Callendret, Benoit
    Heijnen, Esther
    VACCINE, 2024, 42 (26)
  • [8] A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants
    Bernstein, David I.
    Falloon, Judith
    Yi, Tingting
    VACCINE, 2011, 29 (40) : 7042 - 7048
  • [9] Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan
    Tsuchiya, Yumi
    Tamura, Hiroshi
    Fujii, Koji
    Numaguchi, Hirotaka
    Toyoizumi, Kiichiro
    Liu, Tina
    Le Gars, Mathieu
    Cardenas, Vicky
    Eto, Takashi
    VACCINE, 2023, 41 (09) : 1602 - 1610
  • [10] Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
    Hernandez-Bernal, Francisco
    Ricardo-Cobas, Maria C.
    Martin-Bauta, Yenima
    Navarro-Rodriguez, Zadis
    Pinera-Martinez, Marjoris
    Quintana-Guerra, Joel
    Urrutia-Perez, Karen
    Urrutia-Perez, Klaudia
    Chavez-Chong, Cristina O.
    Azor-Hernandez, Jorge L.
    Rodriguez-Reinoso, Jose L.
    Lobaina-Lambert, Leonardo
    Colina-Avila, Elizabeth
    Bizet-Almeida, Jacqueline
    Rodriguez-Nuviola, Jeniffer
    del Valle-Pinera, Sergio
    Ramirez-Dominguez, Mayara
    Tablada-Ferreiro, Elisangela
    Alonso-Valdes, Marel
    Lemos-Perez, Gilda
    Guillen-Nieto, Gerardo E.
    Palenzuela-Diaz, Ariel
    Noa-Romero, Enrique
    Limonta-Fernandez, Miladys
    Fernandez-Avila, Juan M.
    Ali-Mros, Nabil A.
    del Toro-Lahera, Lianne
    Remedios-Reyes, Rossana
    Ayala-Avila, Marta
    Muzio-Gonzalez, Verena L.
    ECLINICALMEDICINE, 2022, 46
12